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Purpose: To evaluate the potential of gene therapy with a recombinant adeno-associated virus vector encoding the
interleukin-1 receptor antagonist gene (rAAV-IL-1Ra) in the treatment of experimental uveitis.
Methods: The vitreal cavity of New Zealand white rabbits was injected with rAAV-IL-1Ra (4×107 infectious units), and
the contralateral eye was injected with the same amount of rAAV-LacZ or PBS as a control. Transgene expression was
evaluated by immunohistochemistry, ELISA, and RT-PCR. To evaluate the therapeutic potential of rAAV-IL-1Ra,
experimental uveitis was induced by intravitreal injection of IL-1α at 10 and 100 days after rAAV–IL-1Ra administration.
The effects of rAAV-IL-1Ra on experimental uveitis were investigated using histological and aqueous analysis.
Results: Following intravitreal injection of rAAV-IL-1Ra, transgene expression was found in various cell types of the
ocular tissues, such as ciliary epithelial cells, retinal ganglion cells, and retinal pigment epithelial cells. RT-PCR and
ELISA showed that the IL-1Ra transgene persisted in the rabbit eye for at least 100 days. Compared with the control eyes,
the transgene expression ameliorated experimental uveitis at 10 and 100 days after a single administration of rAAV-
IL-1Ra.
Conclusions: Intravitreal administration of rAAV-IL-1Ra led to sustained human IL-1Ra transgene expression in rabbit
eyes for 100 days. The transgene expression suppressed uveitis episodes at 10 and 100 days after rAAV-IL-1Ra injection.
Long-term suppression of experimental uveitis could be achieved by gene therapy with rAAV-IL-1Ra.
Uveitis  is  the  most  common  form  of  intraocular
inflammation. Uveitis affects 0.2% of the population and has
an annual incidence of 8.2 new cases per 100,000 people [1].
The process of uveitis is refractory and recurrent [2]. The
duration of chronic uveitis can exceed three months and that
of acute anterior uveitis more than four weeks [2,3]. Fifty
percent of uveitis patients experience recurrent episodes that
may  lead  to  serious  and  vision-threatening  ocular
complications [2,3].
Steroid  therapy  is  the  current  principle  treatment  for
uveitis [4]. However, long-term administration of steroids is
complicated by many side effects, such as infection, cataracts,
and glaucoma [4-6]. Therefore, the development of alternative
treatments  to  control  this  intraocular  inflammation  is
necessary.
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The  interleukin-1  receptor  antagonist  (IL-1Ra)  is  a
member of the IL-1 family. IL-1Ra binds to the IL-1 receptor
but does not induce any intracellular response [7-10]. Previous
studies  have  reported  that  IL-1Ra  improves  many  ocular
inflammatory  diseases,  such  as  conjunctivitis  and  corneal
graft  rejection  [11,12].  Experimental  uveitis  can  also  be
suppressed  by  administration  of  IL-1Ra  protein  [13,14].
However, as the half-life of IL-1Ra protein is short (15–25
min), it is thus impractical for clinical uveitis therapy [15].
Advances in molecular biology suggest that gene therapy
with the IL-1Ra-encoding gene has potential for the treatment
of uveitis. If the IL-1Ra-encoding gene can be delivered into
the target cells and this results in the stable expression of that
gene, such a strategy may overcome the problem of the short
half-life of functional IL-1Ra protein. To date, naked DNA-,
retroviral-, and adenovirus-based vectors have been studied
as potential agents in ocular gene therapy [16,17]. However,
the studies mentioned above indicate that these vectors have
some  limitations  in  achieving  ideal  ocular  gene  therapy,
including  poor  delivery  efficiency,  lack  of  sustained
expression, and host immune reactions [17-19]. The adeno-
associated virus (AAV) is a promising gene delivery system
because this vector might be used to deliver appropriate genes
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1542into  diverse  cell  types  in  many  tissues  without  causing
significant  host  immune  reactions  [18,20,21].  There  are
reports of recombinant AAV (rAAV) vectors that can deliver
a transgene into the cells of various tissues, such as the central
nervous system, muscle, lung, and gut, and produce long-term
expression [18,20,21]. In our previous studies, we found that
an rAAV vector can efficiently deliver the transgene into
various cells in joint and ocular tissues and produce long-term
expression, and that experimental arthritis can be suppressed
and prevented by gene therapy with rAAV-IL-1Ra [22,23].
These findings have led us to further explore the potential of
using an rAAV vector to deliver the IL-1Ra-encoding gene
for uveitis gene therapy.
In this study, we evaluated the effects of gene therapy
with rAAV-IL-1Ra on experimental uveitis. The rAAV vector
encoding the human IL-1Ra-encoding gene, which is driven
by  the  human  cytomegalovirus  (CMV)  promoter,  was
introduced into the eyes of rabbits by intravitreal injection.
The expression of the rAAV-mediated transgene in ocular
tissue and the effects of rAAV-IL-1Ra on experimental uveitis
were evaluated.
METHODS
Animals and experimental uveitis: New Zealand white rabbits
(weighing  2–3  kg)  were  handled  in  accordance  with  the
ARVO  guidelines.  The  rabbits  were  anesthetized  by
intramuscular injection containing a mixture of 35–50 mg/kg
ketamin and 8–12 mg/kg xylazine. Experimental uveitis was
induced by interleukin-1 (IL-1) α [14,24]. In summary, human
IL-1 α (Sigma, St. Louis, MO) was dissolved in distilled water
with gentle sonication and diluted to 0.5 ng/μl in PBS. Ten
nanograms (ng) of IL-1 alpha was injected into the vitreal
cavity of the rabbit eye through the pars plana using a 30 gauge
needle. After injection, gentamicin ointment was applied.
Vector construction and rAAV production: Human IL-1Ra
complementary  DNA  (cDNA)  was  obtained  by  reverse
transcription-polymerase  chain  reaction  (RT-PCR)  from
RNA prepared from U937 cells that were treated with phorbol
ester for 48 h [10]. The forward primer used in the PCR
reaction was 5′-TA gcg gcc gc ATG GAA ATC TGC-3′,
which not only spans the regions converting the initiation
codon  (underlined)  and  its  flanking  sequences  but  also
contains a Not I site (the lowercase letter) at the 5′ end. The
reverse primer was 5′-AA gcg gcc gc CTA CTC GTC CCT
C-3′, which not only spans the stop codon (underlined) and its
flanking  sequences  but  also  contains  a  Not  I  site  (the
lowercase letter) at the 5′ end [22]. The IL-1Ra gene was
cloned between the two Not I sites of pXX-UF1 to replace the
green fluorescent protein gene, and was thus placed under the
transcription  regulation  of  the  human  cytomegalovirus
(CMV)  immediate-early  promoter.  Recombinant  AAV
encoding human IL-1Ra cDNA was constructed using a three-
plasmid cotransfection system, as previously described in the
literature [22,23,25-27]. Titers of rAAV-LacZ and rAAV-
IL-1Ra were determined by dot-blot hybridization.
Histochemical detection of β-galactosidase: Rabbit eyes were
enucleated  and  prefixed  by  immersion  in  4%
paraformaldehyde-PBS  (pH  7.4)  on  ice  for  15  min.  The
eyeballs were rinsed twice in PBS and then incubated in a dark
room for 12 h at 37 °C with 5-bromo-4-chloro-3-indolyl-β-D-
galactosidase (X-gal; Calbiochem, La Jolla, CA) in a solution
containing 10 mM K3Fe(CN)6, 10 mM K4Fe(CN)6, 2 mM
MgCl2, 0.01% deoxycholate, and 0.02% NP40 in PBS (pH
7.8). The eyes were postfixed for 6 h in 2% glutaraldehyde
and  4%  formaldehyde-PBS  (pH  7.0),  cryoprotected  by
sequential soaking in 10% and 30% sucrose solution, placed
in  optimal  cutting  temperature  (OCT)  compound  (Miles
Laboratories, Elkhart, IN), and then snap frozen in liquid
nitrogen  and  cut  into  8  μm  sections.  The  sections  were
counterstained with eosin and examined for the E. coli β-
galactosidase (LacZ) gene signal.
Immunohistochemistry assay: The rabbits were euthanized by
intracardial  injection  with  pentobarbital,  and  the  eyes
removed  and  quick-frozen  in  OCT  embedding  compound
(Miles  Laboratories).  Ten-micrometer  sections  were  cut,
mounted on microscope slides, and then air-dried for 30 min.
After fixation in 4% paraformaldehyde for 1 h, sections were
rinsed  in  PBS  and  the  endogenous  peroxidase  was  then
quenched with 1.0% H2O2 for 5 min at room temperature. The
sections were rinsed twice in PBS, and then blocked with a
mixture of 5% bovine serum albumin and 0.3% Triton X-100
in PBS for 30 min. A goat polyclonal antibody to human
IL-1Ra (R&D Systems, Minneapolis, MN) was added to the
sections  for  1  h.  Primary  antibodies  were  localized  by
immunoperoxidase  staining  (R&D  Systems).  The  sections
were then washed three times with PBS, followed by the
addition of biotinylated anti-goat secondary antibodies for 1
h. After rinsing in PBS, the samples were incubated with
streptavidin-peroxidase  for  30  min.  After  washing,  the
sections were reacted with the DAB (3,3-diaminobenzidine
tetrahydrochloride)  chromogen.  The  sections  were  rinsed
with  distilled  water  and  counterstained  with  hematoxylin.
They were then mounted on microscope slides using a xylene-
based mounting medium, and observed under a microscope.
Reverse transcription-polymerase chain reaction (RT-PCR):
The  eyeballs  were  enucleated  and  frozen  immediately  in
liquid nitrogen. The samples were homogenized in guanidine
thiocyanate,  and  total  RNA  was  extracted  by  phenol-
chloroform. One microgram of the RNA was used for reverse
transcription. Complementary DNA was synthesized using
oligo(dT)  as  a  primer  and  200  IU  of  SuperScript  II
transcriptase (Gibco BRL, Gaithersburg, MD) according to
the manufacturer’s instructions. PCR amplification was done
as described above for vector construction. The housekeeping
gene, Βeta-actin, served as a control to ensure that equal
amounts  of  RNA  were  analyzed  from  each  sample.  The
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GCG AGA AGA TGA CC-3′, and the reverse primer was 5′-
GAA GTC CAG GGC GAC GTA GCA C-3′, which was
expected to produce a 350 bp DNA fragment [25]. The PCR
products were separated by 1% agarose gel electrophoresis,
stained with ethidium bromide, and photographed.
Enzyme-linked  immunosorbent  assay  (ELISA):  The  rabbit
eyes were enucleated and uveoretinal tissues such as the iris,
ciliary body, retina, and choroid-sclera were harvested. The
collected  tissues  were  homogenized  in  10–20  volumes  of
homogenization buffer (50 mM Tris, 0.3MNaCl, and 0.3%
Triton  X-100)  containing  protease  inhibitors  (0.1  mM
phenylmethylsulfonyl  fluoride,  0.1  mM  benzethonium
chloride,  1  mM  benzamidine,  1  mM
ethylenediaminetetraacetic acid, and 200 KIU/ml aprotinin).
The homogenates were centrifuged at 14,000x g for 30 min.
The  supernatants  were  collected  and  total  protein
concentrations were detected using the Bio-Rad protein assay
system  (Bio-Rad  Laboratories,  Hercules,  CA).  Human
interleukin-1Ra  levels  were  determined  with  a  sandwich
enzyme-linked  immunosorbent  assay,  according  to  the
manufacturer’s instructions (R&D Systems) [27,28].
Aqueous cell counting and protein concentration: Rabbits
were prepared and anesthetized as usual. The aqueous humor
was aspirated by puncturing the anterior chamber with a 30
gauge needle, and the fluid loaded onto a hemocytometer for
aqueous  cell  counting  [14,29].  To  determine  protein
concentration, the aqueous humor was centrifuged at 3,000
rpm for 5 min to remove cell debris. The supernatant was
collected, and the protein concentration determined by the
Lowry method [14,30].
HE  staining:  The  eyes  were  enucleated  and  fixed  in  4%
paraformaldehyde for 24 h. The fixed tissue was embedded in
paraffin.  Ten  μm  sections  were  cut  and  mounted  on
microscope  slides,  and  the  sections  were  stained  with
hematoxylin  and  eosin.  These  slides  were  examined  and
photographed under a microscope.
Statistical analysis: One-way ANOVA tests were used to
analyze  the  differences  between  experimental  and  control
groups (rAAV-LacZ and PBS) in each assay. All data were
expressed as mean ±standard deviation. If the overall F-test
was significant, Tukey post-hoc comparisons were used to
detect significant differences among different groups. The p-
value < 0.01 was considered significant.
RESULTS
Experimental uveitis: To study the potential effects of rAAV-
IL-1Ra on uveitis, we needed to establish an animal model of
experimental uveitis. Experimental uveitis was induced by
intravitreal injection of IL-1α (10 ng) in New Zealand white
rabbits (Figure 1C,E,G). The contralateral eye was injected
with the same amount of the vehicle (distilled water; Figure
1D,F,H) to serve as a control [14,24,30]. Inflammation was
evaluated by the presence of leukocyte infiltration. Before
IL-1α or vehicle injection, no signs of inflammation were
found in the ocular tissues (Figure 1A,B). Following IL-1α
injection,  profound  leukocyte  infiltration  and  protein
accumulation were observed in the tissues of the anterior
ocular  segment.  The  inflammation  was  noted  within  6  h,
peaked  at  24  h  (Figure  1C,  arrowhead),  and  decreased
thereafter.  Three  days  after  IL-1α  injection,  moderate
inflammation  was  seen  (Figure  1E),  and  at  15  days  after
injection,  no  inflammation  was  identified  in  the  anterior
ocular segment (Figure 1G). Experimental uveitis was not
detected in the control eyes at 1, 5, and 15 days after vehicle
injection (Figure 1B,D,F,H, respectively). The histological
findings  demonstrated  that  experimental  uveitis  could  be
induced by intravitreal injection of IL-1α and that the uveitis
subsided within 15 days.
Transgene expression in rabbit eyes: To localize the rAAV-
mediated transgene expression, the expression of the IL-1Ra
transgene was detected immunohistochemically in the ocular
tissue  of  rabbit  eyes.  Brown  staining  was  detected  in  the
rAAV-IL-1Ra-injected  eyes.  IL-1Ra  expression  was
observed  as  brown  staining  in  various  cell  types  in  the
uveoretinal tissues, including retinal ganglion cells (Figure
2A,  arrowhead)  and  ciliary  epithelial  cells  (Figure  2C,
arrowhead) in all 10 rabbits. Retinal pigment epithelial (RPE)
cells located in the peripheral retina also stained positively in
two of the 10 rabbits’ eyes (Figure 2A, arrow). However, no
positive staining was observed in the control eyes (Figure
2B,D).
To further evaluate the expression of the rAAV-mediated
transgene in the rabbit eye, IL-1Ra transgene expression was
followed for 100 days. RT-PCR was used to detect mRNA
expression  of  the  IL-1Ra  transgene  in  the  rabbit  eyes.
Intravitreal injection with rAAV-IL-1Ra (4×107 infectious
units; n=5) was performed in the right eye, and the same
amount of rAAV-LacZ (n=5) was injected into the left eye. In
another  group,  the  right  eye  was  injected  with  the  same
amount  of  PBS  (n=5).  At  10  days  after  rAAV-IL-1Ra
injection, significant IL-1Ra transgene expression was seen
in  the  rAAV-IL-1Ra-injected  eyes  (Figure  3,  lane  3).  In
contrast, no IL-1Ra gene expression was observed in rAAV-
LacZ-injected eyes (Figure 3, lane 1) or PBS-injected eyes
(Figure 3, lane 2). To further evaluate whether the rAAV-
mediated transgene was expressed for a long time in rabbit
eyes, the right eyes were treated with intravitreal injection of
rAAV-IL-1Ra (4×107 infectious units; n=5), and the left eyes
were treated with the same amount of rAAV-LacZ (n=5). In
another  group,  the  right  eye  was  injected  with  the  same
amount  of  PBS  (n=5).  At  100  days  after  rAAV-IL-1Ra
injection, the rabbit eyes were isolated for RT-PCR. In the
control group, no transgene expression was detected in rAAV-
LacZ-injected eyes (Figure 3, lane 4) or PBS-injected eyes
(Figure 3, lane 5). In contrast, mRNA of IL-1Ra was still
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1544Figure 1. Establishment of experimental uveitis. The vitreal cavity of rabbit eyes was injected with IL-1α to induce experimental uveitis, and
the contralateral eye was injected with the same amount of the vehicle (distilled water) as a control. Inflammation was evaluated by the presence
of leukocyte infiltration (arrowheads) in the tissues of the anterior ocular segment. Immediately before IL-1α or vehicle injection, no leukocyte
infiltration was observed (A, B). The inflammation, defined as the presence of massive leukocyte infiltration in the tissue of the anterior ocular
segment, peaked one day after IL-1α injection (C). Three days after IL-1α injection, the inflammation had partially subsided (E), and 15 days
after injection, no sign of inflammation was seen in the anterior ocular segment (G). Experimental uveitis was not detected in the control eyes
at 1, 5, or 15 days after vehicle injection in the control group (B, D, F, H). The scale bar in H is equal to 100 μm.
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1545detected in rAAV-IL-1Ra-injected eyes (Figure 3, lane 6). To
quantify the expression of the rAAV-mediated transgene in
the rabbit eyes, the IL-1Ra protein was measured at 10 and
100  days  after  rAAV-IL-1Ra  injection  (Table  1).  A  high
concentration of human IL-1Ra protein was found in the eyes
at 10 days (67.86±3.91 pg/g; n=5) and at 100 days (63.17±4.13
pg/g;  n=5)  after  rAAV-IL-1Ra  injection.  No  significant
IL-1Ra protein (<1.0 pg/g) was detected in the eyes injected
with rAAV-LacZ or PBS at 10 or 100 days after intravitreal
injection.  This  finding  suggested  that  the  rAAV  vector
delivered the human IL-1Ra gene into the rabbit eye and
resulted in functional IL-1Ra protein expression.
Gene  therapy  with  rAAV–IL-1Ra  ameliorated  induced
experimental  uveitis  at  10  days  after  rAAV–IL-1Ra
administration: The effects of rAAVIL-1Ra on experimental
uveitis  were  examined  in  16  rabbits.  Ten  were  given
intravitreal injection of AAV-IL-1Ra (4×107 infectious units)
in the right eye, and the left eye was injected with rAAV-LacZ.
In another six rabbits, the same amount of PBS was injected
into the right eye. Ten days later, experimental uveitis was
induced by intravitreal injection of IL-1α. At 24 h after uveitis
induction, the effect of rAAV-IL-1Ra on experimental uveitis
was investigated by histological examination (Figure 4) and
aqueous analysis (Figure 5). In the control eyes, histological
Figure  2.  rAAV-mediated  human
IL-1Ra transgene expression in rabbit
eyes. The vitreal cavity of rabbit eyes
was injected with rAAV-IL-1Ra (4×107
infectious units), and the contralateral
eye was injected with the same amount
of rAAV-LacZ or PBS as a control. Ten
days later, the rabbit eyes were removed
and  processed  for
immunohistochemistry.  In  rAAV-
IL-1Ra-injected  eyes,  transgene
expression was found in various ocular
tissue  cell  types,  including  retinal
ganglion  cells  (A,  arrowhead),  retinal
pigment epithelial cells (A, arrow), and
ciliary epithelial cells (C, arrowhead).
No human IL-1Ra transgene expression
was detected in the control eyes (B and
D). The scale bar in D is equal to 25 μm.
Figure 3. RT-PCR analysis. The vitreal
cavity of rabbit eyes was injected with
rAAV-IL-1Ra (4×107 infectious units),
and the contralateral eye was injected
with the same amount of rAAV-LacZ.
In  another  group,  the  right  eye  was
injected with the same amount of PBS.
Ten  days  later,  the  rabbit  eyes  were
enucleated, extracted, and subjected to
RT-PCR. No human IL-1Ra mRNA was
observed  in  the  rAAV-LacZ-injected
(lane 1) or PBS-injected (lane 2) eyes.
Significant  transgene  expression  was
observed  in  rAAV-IL-1Ra-injected
eyes (lane 3). After 100 days, the eyes
of  different  rabbits  were  enucleated,
extracted, and subjected to RT-PCR. No
human IL-1Ra mRNA was found in the
rAAV-LacZ-injected (lane 4) or PBS-
injected  (lane  5)  eyes.  Significant
transgene expression was still detected
in the rAAV-IL-1Ra-injected eye (lane
6). Lane M shows the molecular weight
markers.
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1546examination  showed  massive  leukocyte  infiltration  and
exudate accumulation in the tissues of the anterior ocular
segment of rAAV-LacZ-injected eye (Figure 3B) and PBS-
injected  eyes  (Figure  3E).  Aqueous  analysis  was  used  to
further  investigate  the  effect  of  rAAV-IL-1Ra  on  the
development of experimental uveitis. The aqueous cell counts
were  887±91  cells/μl  in  rAAV-LacZ-injected  eyes  and
1,032±127 cells/μl in PBS-injected eyes (Figure 5A). The
protein  concentration  was  21.4±3.3  μg/μl  in  rAAV-LacZ-
injected eyes and 20.6±2.9 μg/μl in PBS-injected eyes (Figure
5B).  The  eyes  treated  with  rAAV-IL-1Ra  showed  greatly
attenuated  inflammation.  The  histological  examination
showed  minimal  leukocyte  infiltration  and  exudate
accumulation in the eyes injected with rAAV-IL-1Ra (Figure
4H), and the rAAV-IL-1Ra-treated eyes had a low aqueous
cell count of 173± 2 cells/μl; p <0.01 (Figure 5A) and a protein
concentration of 9.7±1.3 μg/μl; p <0.01 (Figure 5B). This
finding indicated that rAAV delivered the IL-1Ra transgene
into  the  rabbit  eyes  and  that  the  transgene  expression
suppressed experimental uveitis 10 days after rAAV-IL-1Ra
injection.
Gene  therapy  with  rAAV-IL-1Ra  suppressed  induced
experimental  uveitis  at  100  days  after  rAAV–IL-1Ra
administration: The effects of rAAV-IL-1Ra on experimental
uveitis  were  examined  in  16  rabbits.  Ten  were  given
intravitreal injection of rAAV-IL-1Ra (4×107 infectious units)
in the right eye, and the left eye was injected with rAAV-LacZ.
In another six rabbits, the same amount of PBS was injected
in the right eye. After 100 days, experimental uveitis was
induced by an intravitreal injection of IL-1α in the eye. At 24
h after uveitis induction, the therapeutic effect of IL-1Ra on
experimental  uveitis  was  evaluated  by  histological
examination (Figure 6) and aqueous analysis (Figure 7). In the
control  eyes,  histological  examination  showed  massive
leukocyte infiltration and exudate accumulation in the tissues
of the anterior ocular segment (Figure 6B). Aqueous analysis
was used to investigate the effects of rAAV-IL-1Ra on this
uveitis episode. The aqueous cell count was 936±103 cells/
μl in rAAV-LacZ-injected eyes and 874±93 cells/μl in PBS-
treated eyes (Figure 7A). Protein concentration was 19.2±2.4
μg/μl  in  rAAV-LacZ-injected  eyes  and  20.4±3.3  μg/μl  in
PBS-injected eyes (Figure 7B). The eyes treated with rAAV–
IL-1Ra showed greatly attenuated inflammation. Pathological
examination  showed  minimal  leukocyte  infiltration  and
exudate accumulation in the eyes injected with rAAV-IL-1Ra
(Figure 6E). The aqueous fluid from the eyes treated with
rAAV-IL-1Ra had low cell counts of 203±21 cells/μl; p <0.01
(Figure 7A) and protein concentrations of 11.4±1.3 μg/μl;
p <0.01 (Figure 7B). Our study showed that IL-1Ra transgene
expression  retained  the  ability  to  suppress  experimental
uveitis at 100 days after rAAV-IL-1Ra administration.
DISCUSSION
Uveitis  is  the  most  common  intraocular  inflammation.  It
results from disruption of the blood–ocular barrier and is
characterized by leukocyte infiltration and protein leakage
[1,7,31]. Although the etiology and pathogenesis of uveitis are
not  well  elucidated,  there  are  several  animal  models  for
understanding disease pathogenesis and testing new therapies
for  ocular  inflammatory  diseases,  such  as  IL-1  induced
uveitis, experimental autoimmune uveitis (EAU), endotoxin-
induced  uveitis  (EIU),  etc  [24,30,32,33].  Among  these
models, IL-1 induced experimental uveitis is considered to be
an animal model for acute anterior ocular inflammation. This
inflammation  is  characterized  by  protein  leakage  in  the
anterior  chamber  and  by  infiltration  of  macrophages  and
neutrophils into the eye, with a peak at 24 h after IL-1 injection
[24,32]. Past studies have also revealed that IL-1 may activate
the T cell-mediated immune response and thereby play an
important role in the pathogenesis of recurrent uveitis [34,
35]. Furthermore, previous investigations have reported that
IL-1 contributed to the local inflammatory response during
primary  infections  or  during  recurrent  episodes  of
toxoplasma-induced  retinochoroiditis  [36].  These  clinical,
immunological, and histological characteristics make IL-1
induced uveitis a suitable in vivo model to gain information
regarding  the  immunopathogenesis  and  treatment  of
inflammatory ocular diseases in humans.
In  this  study,  we  administered  rAAV-IL-1Ra  to  the
peripheral retina and found that the rAAV vector efficiently
delivered  the  transgene  to  the  ganglion  cell  and  ciliary
epithelial cells in all rAAV-IL-1Ra-injected eyes. Efficiency
TABLE 1. ELISA IDENTIFICATION OF HUMAN IL-1RA IN THE RABBIT EYE AFTER RAAV-IL-1RA INJECTION.
Concentration
Groups
rAAV-IL-1-Ra rAAV-LacZ PBS
IL-1-Ra (pg/gm)
10 days
67.86±3.91* < 0.1 < 0.1
IL-1-Ra (pg/gm)
100 days
63.17±4.13* < 0.1 < 0.1
rAAV-IL-1RA was injected intravitreally into the right eyes of rabbits, and the left eyes were treated with the same amount of
rAAV-LacZ or PBS. At 10 and 100 days after rAAV transduction, the entire uveoretinal tissue of each eye was harvested and
processed for ELISA. The asterisk indicates statistically significant differences.
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1547is critical for successful ocular gene therapy. In this study, the
AAV vector used was the AAV2 serotype, because this vector
can  transfer  the  gene  into  various  ocular  cells  through
intravitreal or subretinal injection. Over 100 different AAV
serotypes have been described, several of which have already
been tested in vivo in animals [37-39]. In ocular gene therapy,
AAV vectors based on serotypes 1, 2, 4, and 5 have been
evaluated after intravitreal and subretinal injection [37,39]. Of
these, AAV2 is considered the only vector able to efficiently
transduce cells into the inner retinal layers after intravitreal
injection [27,37,39,40]. Previous research has reported that
intravitreal injection of AAV2 led to the transduction of retinal
ganglion cells and various cells of the inner nuclear layer for
months  [27,29,40].  Past  studies  have  also  revealed  that
subretinal injection of the AAV2 vector delivering a reporter
gene results in transduction of RPE and photoreceptor cells in
adult mice [26,37,39]. On the other hand, AAV1, 4, and 5
vectors delivered transgenes efficiently to the photoreceptor
and pigment epithelium after subretinal injection. However,
little transgene expression is observed following intravitreal
injection of these vectors [37,39]. Therefore, the AAV2 vector
was chosen to be tested for potential uveitis gene therapy. In
this study, we also found transgene expression in RPE cells in
two of the 12 injected eyes. This transgene expression in RPE
cells was found in the retina adjacent to the injected site. We
assume that the rAAV vector may penetrate or infiltrate into
the subretinal space at the junction of the pars plana and
peripheral  retina,  because  the  retina  around  this  area  is
relatively thin and attached loosely to choroid.
Our  results  also  indicate  that  experimental  uveitis
induced  by  IL-1  at  10  and  100  days  after  rAAV-IL-1Ra
administration could be suppressed by a single intravitreal
injection of rAAV-IL-1Ra. Previous studies have reported
that  IL-1Ra  is  a  potential  anti-inflammatory  agent  in  the
treatment of uveitis [14,30,41]. The IL-1Ra is an endogenous
peptide that binds to IL-1 receptors but does not induce any
intracellular response [8]. IL-1Ra may suppress experimental
uveitis by protecting the blood–ocular barrier from disruption
Figure 4. Histological findings in the rabbit eye with induced uveitis at 10 days after rAAV-IL-1Ra administration. The vitreal cavity of rabbit
eyes was injected with rAAV-IL1-Ra, and the contralateral eye was injected with the same amount of rAAV-LacZ. In another group, the right
eye was injected with the same amount of PBS. After 10 days, uveitis was induced by intravitreal injection of IL-1α. The eyeballs were
enucleated, fixed, and stained with H & E immediately before, or one or three days after, uveitis induction. In the eyes injected with rAAV-
LacZ, the time points are immediately before (A), one day after (B), and three days after (C) uveitis induction. In the eyes injected with PBS,
the time points are immediately before (D), one day after (E) and three days after (F) uveitis induction. In the eyes injected with rAAV-IL-1Ra,
the time points are immediately before (G), one day after (H), and three days after (I) IL-1α injection. The scale bar in I is equal to 100 μm.
Molecular Vision 2009; 15:1542-1552 <http://www.molvis.org/molvis/v15/a165> © 2009 Molecular Vision
1548by IL-1 stimulation [14,30]. Because the amino acid sequence
of human IL-1Ra shows 77% homology to that of rabbit
IL-1Ra,  Rosenbaum  et  al.  [14]  reported  that  intravitreal
injection with functional human IL-1Ra protein successfully
inhibits  experimental  uveitis  in  rabbits.  Moreover,  the
functional  human  IL-1Ra  protein  expression  in  the  cells
transduced by the rAAV vector in this study might be effective
in  protecting  the  blood–ocular  barrier  from  IL-1  insult.
Previous research has also shown that these transduced cells
are important for maintaining the blood–ocular barrier, which
includes the zonula occludens between the ciliary epithelial
cells, tight junctions between retinal vessel endothelial cells,
and tight junctions between RPE cells [31]. Therefore, we
observed that experimental uveitis was ameliorated at 10 days
Figure 5. Aqueous humor analysis in the
rabbit  eye  with  induced  uveitis  at  10
days  after  rAAV-IL-1Ra
administration.  The  vitreal  cavity  of
rabbit  eyes  was  injected  with  rAAV-
IL1-Ra, and the contralateral eye was
injected with the same amount of rAAV-
LacZ. In another group, the right eye
was injected with the same amount of
PBS. After 10 days, uveitis was induced
by intravitreal injection of IL-1α. At 24
hours  after  uveitis  induction,  the
aqueous fluid was aspirated for analysis.
The  effect  of  rAAV-IL-1Ra  was
evaluated  by  comparing  aqueous  cell
counts  (A)  and  protein  concentration
(B)  in  the  experimental  and  control
groups.  Values  represent  the  mean
±standard  deviation.  The  asterisk
indicates  statistically  significant
differences.
Figure 6. Histological findings in the eye with induced uveitis at 100 days after rAAV-IL-1Ra administration. The vitreal cavity of rabbit eyes
was injected with rAAV-IL1-Ra, and the contralateral eye was injected with the same amount of rAAV-LacZ. In another group, the right eye
was injected with the same amount of PBS. After 100 days later, uveitis was induced by intravitreal injection of IL-1α. Immediately before,
and one or three days after, uveitis induction, the eyeballs were enucleated, fixed, and stained with H&E. Histology of eyes injected with
rAAV-LacZ immediately before (A), one day after (B), and three days after (C) IL-1α injection. Histology of the eyes injected with rAAV-
IL-1Ra immediately before (D), one day after (E), and three days after (F) IL-1α injection. The scale bar in F is equal to 100 μm.
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1549after rAAV-IL-1Ra injection. Moreover, the observation that
rAAV-mediated transgene expression persisted for at least
100  days  also  explains  that  induced  experimental  uveitis
episodes can be suppressed at 100 days after rAAV-IL-1Ra
administration.
Although gene therapy with rAAV vectors is a promising
approach in the treatment of experimental uveitis, there are
still  several  improvements  required  to  achieve  practical
management in the treatment of clinical uveitis in humans.
Previous  research  has  revealed  that  transgene  expression
decreases over time because most rAAV-mediated transgenes
are episomal, and only a minority integrate randomly into the
host genome [42,43]. Moreover, intravitreal administration of
AAV vectors can elicit neutralizing antibodies against the
vector capsid, thus decreasing the efficiency of therapeutic
gene transfer and preventing effective vector readministration
[44].  Thus,  the  stability  of  rAAV-mediated  transgene
expression  remains  a  challenge.  Furthermore,  long-term
constitutive  transgene  expression  is  not  always  desirable
under  certain  conditions.  In  diseases  such  as  intraocular
inflammation, the level and timing of transgene expression
must be regulated [23,25]. Gene therapy with cell-specific and
inducible expression systems may offer an attractive strategy
for obtaining therapeutic efficacy and avoiding toxicity [22,
23,25]. Additional modification of the AAV vector design
might  include  a  cell-specific  and  inflammation-inducible
promoter system. In addition, various cell transduction and
exogenous therapeutic gene products may compromise the
functioning of the neuroretina [38]. There is a theoretical risk
associated with gene therapy with an AAV vector, although
previous studies report that the rAAV vector is a safe gene
delivery system [27]. Besides, clinical uveitis can be caused
not only by IL-1 but also by other cytokines such as IL-6,
IL-10, and tissue necrosis factor, etc [30,45,46]. Thorough
investigation of the roles of various cytokines may elucidate
the pathogenesis and provide potential approaches for the
treatment of uveitis. Further investigation is necessary.
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